Effects of the combination of atomoxetine and oxybutynin in Japanese patients with obstructive sleep apnoea: A randomized controlled crossover trial

• DOI: 10.1111/resp.14383
• Publication Date: 2022-10-03T01:24:15Z
• Authors: Toru Kinouchi; Jiro Terada; Seiichiro Sakao; Ken Koshikawa; Tsuyoshi Sasaki; Atsuhiko Sugiyama; Shun Sato; Noriko Sakuma; Mitsuhiro Abe; Kohei Shikano; Nami Hayama; Yuki Shiko; Yoshihito Ozawa; Shinobu Ikeda; Takuji Suzuki; Koichiro Tatsumi
• Keywords: Oxybutynin; Crossover study; Sleep study

Abstract Background and Objective The possibility of combination therapy with atomoxetine (ATO) oxybutynin (OXY) has been suggested for obstructive sleep apnoea (OSA). However, the effectiveness this treatment remains uninvestigated in Japanese OSA patients. Therefore, we performed a randomized, crossover, phase II, single‐centre prospective trial to examine effects ATO–OXY Methods In total, 17 patients participated study. one night 80‐mg ATO plus 5‐mg OXY administration were compared those no medication administered before sleep. primary secondary outcomes comprised apnoea–hypopnoea index (AHI) nadir SpO 2 , drop time architecture, respectively. safety endpoints included drug side adverse events. Results values AHI, 3% oxygen desaturation (ODI), 4% ODI, <90% did not significantly differ between receiving medication. Sleep architecture exhibited significant change: increased stage N1 ( p < 0.0001) decreased N2 = 0.03), rapid eye movement efficiency 0.02). subanalysis demonstrated an obvious decrease AHI five responder Total basal tended be lower responders nonresponders 0.065). No experienced severe events or effects. Conclusion Overall, does reduce patients, although was proportion Future studies identifying response group characteristics are warranted.